Bank of America
FNCH

Bank of America’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Bank of America’s Portfolio FNCH Stock Details FNCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12
Closed -$43 – 8415
2023
Q4 		$43 Buy
+12
New +$47 ﹤0.01% 7523
2023
Q3 		– Sell
-7
Closed -$60 – 8166
2023
Q2 		$60 Buy
7
+5
+250% +$51 ﹤0.01% 7455
2023
Q1 		$22 Sell
2
-267
-99% -$3.54K ﹤0.01% 7568
2022
Q4 		$3.87K Sell
269
-6
-2% -$201 ﹤0.01% 7104
2022
Q3 		$14K Buy
275
+60
+28% +$4.17K ﹤0.01% 7153
2022
Q2 		$18K Buy
215
+32
+17% +$2.74K ﹤0.01% 7218
2022
Q1 		$27K Sell
183
-296
-62% -$68.3K ﹤0.01% 7412
2021
Q4 		$143K Buy
479
+390
+438% +$150K ﹤0.01% 6690
2021
Q3 		$35K Buy
89
+19
+27% +$8.1K ﹤0.01% 7206
2021
Q2 		$30K Sell
70
-23,903
-100% -$10.3M ﹤0.01% 7025
2021
Q1 		$11.6M Buy
+23,973
New +$12.2M ﹤0.01% 2572

Other funds holding FNCH

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America's FNCH Position: Q1 2024 in Review

Bank of America sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q1 2024, closing a stake of 12 shares — an estimated $43 sold.

Bank of America first reported a position in FNCH in Q1 2021 and held it in 11 quarters. The position peaked at $11.6M in Q1 2021. 11 funds tracked by Wall St. Rank hold FNCH as of Q1 2024.

  • Bank of America reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Bank of America sold 12 Finch Therapeutics Group, Inc. Common Stock shares in Q1 2024, an estimated $43.
  • Bank of America first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Bank of America's Finch Therapeutics Group, Inc. Common Stock position peaked at $11.6M in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.